12.57
Amneal Pharmaceuticals Inc stock is traded at $12.57, with a volume of 2.75M.
It is down -0.55% in the last 24 hours and up +9.11% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$12.64
Open:
$12.76
24h Volume:
2.75M
Relative Volume:
1.57
Market Cap:
$3.95B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-18.47
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+2.95%
1M Performance:
+9.11%
6M Performance:
+58.31%
1Y Performance:
+62.19%
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals Inc
|
12.57 | 3.97B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
122.24 | 54.10B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.90 | 46.85B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.90 | 43.82B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.35 | 34.79B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
517.13 | 21.83B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
How Amneal Pharmaceuticals Inc. stock trades during market volatilityJuly 2025 Movers & Low Risk High Win Rate Stock Picks - ulpravda.ru
Assenagon Asset Management S.A. Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Market Leaders: What insider trading reveals about Amneal Pharmaceuticals Inc. stockJuly 2025 Momentum & High Return Stock Watch Alerts - ulpravda.ru
What insider trading reveals about Amneal Pharmaceuticals Inc. stockQuarterly Growth Report & Expert Approved Momentum Trade Ideas - ulpravda.ru
New Highs: Is Amneal Pharmaceuticals Inc. stock overvalued by current metrics2025 Risk Factors & High Accuracy Swing Trade Signals - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reportsJuly 2025 Selloffs & Accurate Intraday Trading Signals - DonanımHaber
Will Amneal Pharmaceuticals Inc. stock recover faster than peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - DonanımHaber
Can Amneal Pharmaceuticals Inc. stock continue upward trendProduct Launch & Low Risk Entry Point Tips - DonanımHaber
Aug Patterns: Why Amneal Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week HighStill a Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $12.69 - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at $12.69 By Investing.com - Investing.com South Africa
How interest rate cuts could boost Amneal Pharmaceuticals Inc. stockMarket Volume Report & Daily Risk Controlled Trade Plans - ulpravda.ru
Why Amneal Pharmaceuticals Inc. stock attracts global investorsMarket Risk Analysis & Real-Time Price Movement Reports - ulpravda.ru
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Decliners & Free High Accuracy Swing Entry Alerts - ulpravda.ru
Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks - Seeking Alpha
Yakima Topic AMNEAL PHARMACEUTICALS, INC. | News, Weather, Sports, Breaking News - KIMA
Squarepoint Ops LLC Buys 420,398 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Esomeprazole Market Set to Witness Significant Growth - openPR.com
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Increased by BlackBarn Capital Partners LP - MarketBeat
A Look at Amneal Pharmaceuticals’ Valuation as New FDA Generics to Restasis and ProAir HFA Expand Growth Prospects - Sahm
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Key FDA Wins For Epinephrine And Complex Generics - Sahm
Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated at Barclays - MarketBeat
Amneal stock rises after FDA approves epinephrine injection By Investing.com - Investing.com Australia
FDA approves Amneal’s epinephrine injection for emergency care By Investing.com - Investing.com Australia
FDA approves Amneal’s epinephrine injection for emergency care - Investing.com
Amneal stock rises after FDA approves epinephrine injection - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Epinephrine Injection, Expanding Its Injectables Portfolio for Emergency Care - Quiver Quantitative
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals - GlobeNewswire
JPMorgan Chase & Co. Buys 240,676 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Arrowstreet Capital Limited Partnership Sells 96,228 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Lifted by Walleye Capital LLC - MarketBeat
Amneal’s Parkinson’s drug shows positive interim results By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Inc Stock Analysis and ForecastFinancial Sector Performance & Outstanding Profit Strategies - earlytimes.in
Amneal receives U.S. FDA approval for albuterol sulfate inhalation aerosol - MSN
Amneal Pharmaceuticals Reports 'Substantial Clinical Benefit' from Crexont in Phase 4 Study - marketscreener.com
Amneal’s Parkinson’s drug shows positive interim results - Investing.com
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease - The Manila Times
Amneal announces positive interim phase 4 Elevate-Pd results with Crexont for Parkinson's disease - marketscreener.com
Will Amneal Pharmaceuticals Inc. stock deliver better than expected guidance2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Amneal (NASDAQ: AMRX) Phase 4 ELEVATE-PD shows CREXONT boosting ‘Good On’ time - Stock Titan
Amneal wins FDA approval for generic albuterol inhaler - World Aerosols
How Amneal Pharmaceuticals Inc. stock compares to market leaders2025 Top Gainers & Consistent Profit Alerts - Newser
How Back-to-Back RESTASIS and PROAIR Generics At Amneal Pharmaceuticals (AMRX) Has Changed Its Investment Story - Yahoo Finance
AT&T sues generic drugmakers over alleged price-fixing scheme - Reuters
FDA approves Amneal’s generic albuterol inhaler By Investing.com - Investing.com Canada
FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals (AMRX) - simplywall.st
Amneal receives FDA approval for Restasis generic - Eyes On Eyecare
FDA Approves Amneal Pharmaceuticals’ Albuterol Sulfate Inhalation Aerosol for Asthma and COPD Treatment - geneonline.com
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05% - Ophthalmology Times
Amneal Pharmaceuticals Receives US FDA Approval for Albuterol Sulfate Inhalation Aerosol - marketscreener.com
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):